36.32

0.47% -0.17

After Hours: 36.20 -0.12 -0.33%

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $36.32, with a volume of 1.45M. It is down -0.47% in the last 24 hours and up +6.82% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Previous Close:

$36.49

Open:

$36.49

24h Volume:

1.45M

Relative Volume:

0.68

Market Cap:

$5.90B

Revenue:

Net Income/Loss:

$-328.94M

P/E Ratio:

-14.83

EPS:

-2.4483

Net Cash Flow:

$-266.00M

1W Performance:

-1.71%

1M Performance:

+6.82%

6M Performance:

+119.19%

1Y Performance:

+645.79%

1-Day Range:

$35.69

$36.92

1-Week Range:

$35.69

$37.58

52-Week Range:

$4.115

$43.73

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

258

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT Cogent Biosciences Inc	36.32	5.92B	0	-328.94M	-266.00M	-2.4483
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Nov-10-25	Upgrade	Stifel	Hold → Buy
Nov-10-25	Upgrade	Wedbush	Neutral → Outperform
Oct-16-25	Initiated	Stifel	Hold
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

Apr 15, 2026

Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock - MSN

Apr 15, 2026

Apr 14, 2026

Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN

Apr 14, 2026

Precision Trading with Cogent Biosciences Inc. (COGT) Risk Zones - Stock Traders Daily

Apr 14, 2026

Apr 13, 2026

Revenue Check: What is the long term forecast for Cogent Biosciences Inc stockSell Signal & Reliable Entry Point Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Does Bezuclastinib’s Real-Time FDA Review and NDA Filing Change The Bull Case For Cogent Biosciences (COGT)? - Yahoo Finance

Apr 11, 2026

COGT (Cogent Biosciences) PE Ratio : At Loss (As of Apr. 11, 2026) - GuruFocus

Apr 11, 2026

Apr 10, 2026

Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST - Sahm

Apr 10, 2026

Apr 09, 2026

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 09, 2026

Apr 08, 2026

Cogent Biosciences (COGT): Billionaire Stan Druckenmiller Admires Upside Potential of This Stock - Insider Monkey

Apr 08, 2026

Apr 06, 2026

Gainers Report: What is the long term forecast for Cogent Biosciences Inc stock2026 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn

Apr 06, 2026

Apr 05, 2026

A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - Sahm

Apr 05, 2026

Apr 04, 2026

COGT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 04, 2026

Cogent Biosciences Inc To Discuss Full SUMMIT Data at ASH Transcript - GuruFocus

Apr 04, 2026

Apr 03, 2026

[Form 4] Cogent Biosciences, Inc. Insider Trading Activity - Stock Titan

Apr 03, 2026

Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail

Apr 03, 2026

Technical Reactions to COGT Trends in Macro Strategies - Stock Traders Daily

Apr 03, 2026

Apr 02, 2026

Cogent Biosciences, Inc.Common Stock (NQ: COGT - The Chronicle-Journal

Apr 02, 2026